Correction to: Anlotinib: First Global Approval.
Following a once-daily on days 1-14 of each 21-day cycle regimen, plasma concentrations of anlotinib reached maximum on day 14 and decreased subsequently with the 7-day rest period until the start of the next treatment cycle [2].